Type your tag names separated by a space and hit enter
Progress in HIV-1 antibody research using humanized mice.
PURPOSE OF REVIEWRecent discoveries of highly potent broadly HIV-1 neutralizing antibodies provide new opportunities to successfully prevent, treat, and potentially cure HIV-1 infection. To test their activity in vivo, humanized mice have been shown to be a powerful model and were used to investigate antibody-mediated prevention and therapy approaches. In this review, we will summarize recent findings in humanized mice that have informed on the potential use of broadly neutralizing antibodies targeting HIV-1 in humans.
RECENT FINDINGSHumanized mouse models have been used to demonstrate the antiviral efficacy of HIV-1 neutralizing antibodies in vivo. It has been shown that a combination of antibodies can suppress viremia below the limit of detection and targets the HIV-1 reservoir. Moreover, passively administered antibodies and vector-mediated antibody production protect humanized mice from HIV-1 infection. Finally, immunization studies in knock-in/transgenic mice carrying human antibody gene segments have informed on potential vaccination strategies to induce broad and potent HIV-1 neutralizing antibodies.
SUMMARYHumanized mouse models are of great value for HIV-1 research. They represent a highly versatile in vivo system to investigate novel approaches for HIV-1 prevention and therapy and expedite the critical translation from basic findings to clinical application.
aInstitute of Virology, University Hospital Cologne bLaboratory of Experimental Immunology, Center for Molecular Medicine Cologne (CMMC), University of Cologne cDepartment I of Internal Medicine, University Hospital Cologne dGerman Center for Infection Research, partner site Bonn-Cologne, Cologne, Germany.
Pub Type(s)Journal Article